Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (301-310 of 471) with videos related to

Pageof 48
Sort By:
American Journal of Hematology|March 15, 2016
Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experienceTaxiarchis V Kourelis, Francis K Buadi, Shaji K Kumar, et al.
Cancer Medicine|October 6, 2020
Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatmentIuliana Vaxman, Abdullah S Al Saleh, Shaji Kumar, et al.
American Journal of Hematology|August 11, 2016
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myelomaPaolo Milani, S Vincent Rajkumar, Giampaolo Merlini, et al.
Blood Advances|July 9, 2021
Prognostic impact of posttransplant FDG PET/CT scan in multiple myelomaMarcella Kaddoura, David Dingli, Francis K Buadi, et al.
Blood Advances|January 25, 2020
Utility of serum free light chain ratio in response definition in patients with multiple myelomaNadine Abdallah, Prashant Kapoor, David L Murray, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|January 11, 2023
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myelomaUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Pageof 48

Showing results (301-310 of 471) with videos related to

Sort By:
Pageof 48
American Journal of Hematology|March 15, 2016
Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experienceTaxiarchis V Kourelis, Francis K Buadi, Shaji K Kumar, et al.
Cancer Medicine|October 6, 2020
Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatmentIuliana Vaxman, Abdullah S Al Saleh, Shaji Kumar, et al.
American Journal of Hematology|August 11, 2016
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myelomaPaolo Milani, S Vincent Rajkumar, Giampaolo Merlini, et al.
Blood Advances|July 9, 2021
Prognostic impact of posttransplant FDG PET/CT scan in multiple myelomaMarcella Kaddoura, David Dingli, Francis K Buadi, et al.
Blood Advances|January 25, 2020
Utility of serum free light chain ratio in response definition in patients with multiple myelomaNadine Abdallah, Prashant Kapoor, David L Murray, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|January 11, 2023
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myelomaUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Pageof 48